Strange new catalyst for gold ($5,000 possible?)

Gold: Now legal tender Most Americans missed this big story, but 1 in 5 states have now made gold and silver coins legal tender. It's just one reason why so many predict gold will soon hit $5,000. And why you need to check out this $6 strategy for gold immediately.

Michael Ambrogi Biography and Net Worth

COO of NovoCure

Michael J. Ambrogi has been appointed as Vice President - Senior Technology Fellow of the Company effective 9/1/2020. He has been our Chief Operating Officer since 2010 and previously served as our U.S. General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing, service and human resources activities worldwide. From 1991 to 2006, Mr. Ambrogi worked for Deka Research and Development Corporation, inventor Dean Kamen’s research and development firm, last serving as general manager. Mr. Ambrogi led Deka’s teams on many products including the Baxter HomeChoice peritoneal dialysis machine, the Davol Hydroflex surgical irrigation device, the Cordis Crowne Stent and the J&J IBOT 3000 mobility system. Earlier in his career, from 1988 to 1990, Mr. Ambrogi was a consultant with McKinsey & Company, a global management consultant firm. Mr. Ambrogi holds a S.B. in mechanical engineering from MIT.

What is Michael J. Ambrogi's net worth?: The estimated net worth of Michael J. Ambrogi is at least $3.59 million as of July 22nd, 2020. Mr. Ambrogi owns 221,167 shares of NovoCure stock worth more than $3,593,964 as of November 5th. This net worth estimate does not reflect any other investments that Mr. Ambrogi may own. Learn More about Michael J. Ambrogi's net worth.
How do I contact Michael J. Ambrogi?: The corporate mailing address for Mr. Ambrogi and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Michael J. Ambrogi's contact information.
Has Michael J. Ambrogi been buying or selling shares of NovoCure?: Michael J. Ambrogi has not been actively trading shares of NovoCure during the last quarter. Most recently, Michael J. Ambrogi sold 42,972 shares of the business's stock in a transaction on Wednesday, July 22nd. The shares were sold at an average price of $67.02, for a transaction totalling $2,879,983.44. Following the completion of the sale, the chief operating officer now directly owns 221,167 shares of the company's stock, valued at $14,822,612.34. Learn More on Michael J. Ambrogi's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 11 times. They sold a total of 11,523 shares worth more than $193,742.47. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

Michael J. Ambrogi Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/22/2020	Sell	42,972	$67.02	$2,879,983.44	221,167
4/14/2020	Sell	27,519	$71.00	$1,953,849.00	243,622
2/25/2020	Sell	11,647	$81.16	$945,270.52	216,873
11/4/2019	Sell	80,819	$79.00	$6,384,701.00	195,743
6/19/2019	Sell	110,868	$60.00	$6,652,080.00	296,542
6/6/2019	Sell	5,999	$54.79	$328,685.21	191,673
6/4/2019	Sell	35,000	$52.62	$1,841,700.00	203,174
4/1/2019	Sell	34,375	$47.39	$1,629,031.25	207,549
2/28/2019	Sell	2,397	$53.68	$128,670.96	171,702
2/4/2019	Sell	58,500	$49.21	$2,878,785.00	184,058
2/1/2019	Sell	37,500	$49.03	$1,838,625.00	184,058
1/9/2019	Sell	100,000	$40.00	$4,000,000.00	221,558
7/2/2018	Sell	57,390	$31.48	$1,806,637.20	174,383
5/1/2018	Sell	60,000	$27.40	$1,644,000.00
4/26/2018	Sell	20,000	$26.01	$520,200.00	166,558
4/18/2018	Sell	40,000	$23.03	$921,200.00	166,558
2/23/2018	Sell	8,458	$19.83	$167,722.14	105,288
11/3/2017	Sell	1,200	$22.00	$26,400.00	24,987
11/1/2017	Sell	24,327	$22.01	$535,437.27	49,514
12/22/2016	Sell	27,500	$8.27	$227,425.00	139,084
12/20/2016	Sell	20,000	$8.62	$172,400.00	179,084
12/19/2016	Sell	20,000	$8.76	$175,200.00	179,084
12/16/2016	Sell	40,000	$8.93	$357,200.00	219,084
12/14/2016	Sell	40,000	$8.97	$358,800.00	259,084
12/12/2016	Sell	15,000	$9.01	$135,150.00	289,084
12/8/2016	Sell	10,000	$8.30	$83,000.00	299,084
12/6/2016	Sell	10,000	$8.24	$82,400.00	309,084
6/8/2016	Sell	20,000	$12.24	$244,800.00	324,084

Michael J. Ambrogi Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $16.25

$15.90

$16.35

50 Day Range

MA: $16.72

$14.54

$19.75

2 Week Range

Now: $16.25

$10.87

$24.74

Volume

22,150 shs

Average Volume

1,302,823 shs

Market Capitalization

$1.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Strange new catalyst for gold ($5,000 possible?)

From Stansberry Research | Ad

Click here for full details.